Clove for Dental Pain and Oral Health

Table of Contents

1. The Ancient Dental Remedy — Han Dynasty to Modern Times
2. How Eugenol Numbs Pain — TRPV1 and TRPA1 Channel Modulation
3. Zinc Oxide Eugenol (ZOE) — The Standard Temporary Dental Material
4. The Alqareer 2006 Trial — Clove vs Benzocaine
5. Gingivitis and Periodontitis — Eugenol Against Oral Pathogens
6. Eugenol Mouthwash and Oral Rinse Formulations
7. Dry Socket (Alveolar Osteitis) — Eugenol Dressings
8. Endodontic Applications — Root Canal Sealers
9. Practical Home Use — Whole Clove, Powder, and Diluted Oil
10. Cautions and Adverse Effects
11. Key Research Papers
12. Connections
13. Featured Videos

The Ancient Dental Remedy — Han Dynasty to Modern Times

The earliest documented use of clove for dental pain comes from the Han Dynasty court of China, where the spice was imported along the Maritime Silk Road from the Maluku Islands (the "Spice Islands" of what is now eastern Indonesia). Han court officials addressing the emperor were required to chew cloves before speaking, ostensibly to freshen the breath but with the side effect of numbing minor toothache. The practice is recorded in materia medica texts dating to the second century BCE.

Avicenna's 11th-century Canon of Medicine — the standard medical textbook of the Islamic Golden Age and, after Latin translation, of medieval European universities for nearly six centuries — recommended clove specifically for "pain of the teeth and gums." The recommendation appears in nearly every European herbal from Culpeper's 1653 Complete Herbal onward. Folk preparations included chewing a whole dried bud held against the affected tooth, applying clove powder mixed with honey or oil, or biting on a cotton wad soaked in clove water.

When 19th-century chemistry isolated eugenol as the principal active constituent (Bonastre, 1827; Ettling, 1834), the way was open to formal pharmaceutical use. By the early 20th century, zinc oxide eugenol cement was a standard dental material, and eugenol itself was listed in the United States Pharmacopeia as a topical dental anesthetic. In the 2006 Alqareer trial, a homemade clove gel showed no significant difference in pain scores from a benchmark synthetic anesthetic, 20% benzocaine gel.

Back to Table of Contents

How Eugenol Numbs Pain — TRPV1 and TRPA1 Channel Modulation

The molecular pharmacology of eugenol's topical anesthetic effect was worked out in the 2000s. Eugenol is a partial agonist at two ion channels expressed on peripheral nociceptive nerve endings:

• TRPV1 (transient receptor potential vanilloid 1) — the receptor activated by capsaicin (chili pepper heat), endogenous arachidonic acid metabolites, and noxious heat above 43°C. Eugenol opens TRPV1, producing the characteristic transient warmth and tingling on first application, then desensitizes the channel over the following minutes, raising the threshold for pain transmission.
• TRPA1 (transient receptor potential ankyrin 1) — the receptor activated by mustard oil, wasabi, cinnamaldehyde, and various electrophilic compounds. Eugenol again acts as a partial agonist with rapid desensitization. The TRPA1 desensitization appears to mediate much of the analgesic effect on dental pulp pain specifically, because TRPA1 is heavily expressed on the C-fiber nociceptors of the dental pulp.

In parallel with TRP channel desensitization, eugenol at higher local concentrations directly inhibits voltage-gated sodium channels on the same nerve endings, producing local-anesthetic-like blockade of action potential propagation. This is a "frequency-dependent" block similar to that of lidocaine, blocking high-firing-rate nociceptive fibers preferentially over low-firing-rate touch fibers.

The combination of TRP desensitization and sodium channel block produces an analgesic effect that begins within 60–90 seconds of topical application and lasts 15–30 minutes per application. Onset is faster than most synthetic topical anesthetics; duration is shorter than lidocaine, which is why eugenol is favored for brief procedures or as a stop-gap before definitive dental care.

Back to Table of Contents

Zinc Oxide Eugenol (ZOE) — The Standard Temporary Dental Material

Zinc oxide eugenol cement is a two-component dental material that, when mixed, forms a hard, set, but not permanently bonded restorative material with analgesic and antimicrobial properties. Mixing zinc oxide powder with eugenol oil produces a chelation reaction that generates zinc eugenolate crystals embedded in a matrix of unreacted zinc oxide. The set material has the following dental-clinical properties:

• Sedative effect on dental pulp — free eugenol slowly leached from the set cement penetrates dentinal tubules and reaches the pulp, where it desensitizes pulpal nociceptors. This is why ZOE is the standard temporary restoration when a tooth is suspected of having reversible pulpitis — the material itself buys the pulp 4–6 weeks to recover before definitive restoration.
• Mild antimicrobial activity — the same eugenol leaching that produces analgesia also inhibits the cariogenic bacteria (Streptococcus mutans, Lactobacillus, Actinomyces) in any residual carious dentin under the restoration.
• Excellent marginal seal — ZOE flows into the dentinal tubules and sets with minimal volumetric change, producing a fluid-tight seal that prevents microleakage.
• Limited mechanical strength — the trade-off. ZOE is not strong enough for permanent restoration; it is used as a temporary material or as a base layer under a stronger permanent restoration.
• Incompatibility with composite resin — eugenol inhibits the free-radical polymerization of methacrylate composites. For that reason dental practice removes any ZOE temporary completely before placing a composite or composite-bonded permanent restoration.

Reinforced ZOE formulations (with added polymethylmethacrylate or alumina fillers) have improved mechanical strength and are used as intermediate restorative materials for temporary crowns and as root canal sealers (see Endodontic Applications below).

Back to Table of Contents

The Alqareer 2006 Trial — Clove vs Benzocaine

The Alqareer, Alyahya, and Andersson 2006 randomized trial published in the Journal of Dentistry is the most-cited modern clinical evidence for clove as a topical dental anesthetic. The trial design was rigorous for its question:

• Population — 73 adult volunteers
• Interventions — four topical preparations applied to maxillary canine buccal mucosa: (1) clove gel (homemade preparation with clove powder in a glycerin base), (2) clove gel placebo (vehicle without clove), (3) a commercial 20% benzocaine gel, (4) benzocaine placebo (vehicle)
• Procedure — after 5 minutes of topical application, a 27-gauge needle was inserted into the mucosa to a depth of 5 mm and pain was rated on a 100-mm visual analog scale
• Blinding — the gels were applied “in a randomized, subject-blinded manner”: the volunteers did not know which gel they received

Results: both the clove gel and the 20% benzocaine gel had significantly lower mean pain scores than the placebos (p=0.005), and “no significant difference was observed between clove and benzocaine regarding pain scores.” The paper's conclusion, stated cautiously, reads: “Clove gel might possess a potential to replace benzocaine as a topical agent before needle insertion.”

The trial does not claim eugenol is equivalent to a deep injected lidocaine block for major dental procedures — it is a topical agent for surface analgesia only. But for the specific clinical question of pre-injection topical numbing, a homemade clove preparation showed no significant difference from a commercial benchmark, with potentially better safety than benzocaine (which has a small but real risk of methemoglobinemia in infants and small children).

Back to Table of Contents

Gingivitis and Periodontitis — Eugenol Against Oral Pathogens

The clinical evidence for clove and eugenol in inflammatory gum disease (gingivitis, periodontitis) is more limited than the topical anesthesia data. Several mechanisms appear to be operating in parallel:

1. Direct antimicrobial activity against periodontal pathogens — in vitro studies show eugenol inhibits the major periodontal pathogens at minimum inhibitory concentrations (MIC) of 0.25–2 mg/mL. Sensitive species include Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola (the "red complex" of severe periodontitis), and Fusobacterium nucleatum. The membrane-disrupting mechanism applies equally to these Gram-negative anaerobes as to other bacteria.
2. Anti-inflammatory effect on the gingival epithelium — eugenol downregulates production of pro-inflammatory cytokines (interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α) by gingival fibroblasts exposed to lipopolysaccharide (LPS) endotoxin from periodontal pathogens. The effect appears to be mediated by partial inhibition of the NF-κB transcription factor pathway.
3. Antioxidant effect on the periodontal pocket — periodontal inflammation produces large quantities of reactive oxygen species from neutrophils. Eugenol's phenolic structure quenches these reactive species and limits collateral tissue damage to the gingival connective tissue and alveolar bone.

Clove-containing mouthwashes, often combined with other plant extracts like neem and tea tree, are used by people for gingivitis, and clove is used in traditional practice for gum inflammation.

Back to Table of Contents

Eugenol Mouthwash and Oral Rinse Formulations

Clove-based oral rinses fall into several categories with different clinical positioning:

• Therapeutic mouthwashes with eugenol as principal active — clinical formulations typically contain 0.1–0.5% eugenol in an aqueous-alcohol base, often combined with menthol and thymol for flavor and synergistic antimicrobial effect. The classic essential-oil mouthwash formulation includes both eucalyptol and thymol but not eugenol; eugenol-specific commercial products are less common in the US but widely sold in India, the UK, and Australia under various brand names.
• Ayurvedic and Traditional Chinese Medicine formulations — clove appears in many Ayurvedic dental powders (often combined with neem, miswak, licorice root, and salt) and in TCM mouth rinses (often with myrrh, sweet flag rhizome, and licorice). These are typically sold as powders for daily home use rather than as commercial mouthwashes.
• Homemade clove water — a folk preparation of 5–10 cloves simmered in 250 mL of water for 10 minutes, strained, and used as an oral rinse. Provides much lower eugenol concentration than commercial products but is essentially zero-cost.
• Clove oil dilutions — concentrated essential oil diluted to 0.5–1% in a carrier (olive oil for direct mucosal application, glycerin for water-based rinses). Higher potency than clove water but with greater risk of mucosal irritation if dilution is inadequate.

Back to Table of Contents

Dry Socket (Alveolar Osteitis) — Eugenol Dressings

Dry socket (alveolar osteitis) is a painful complication of tooth extraction, particularly mandibular third molar extraction, in which the blood clot that normally fills the extraction socket dislodges or fails to form, leaving exposed bone. It occurs in approximately 2–5% of routine extractions and 25–30% of impacted third molar extractions. The pain is severe and typically begins 2–4 days after extraction.

The classical treatment is a medicated dressing placed into the empty socket. The historical and still widely used preparation is a eugenol-based dry-socket paste containing eugenol, butamben (a local anesthetic), and iodoform (an antimicrobial). The eugenol provides immediate analgesia by desensitizing the exposed nociceptors on the bone surface; the butamben provides additional sodium-channel blockade; the iodoform provides slow-release antimicrobial activity against contaminating oral flora.

Plain zinc oxide eugenol cement is also commonly used as a dry socket dressing, particularly when iodoform sensitivity is suspected. The dressing is typically replaced every 24–48 hours for 3–5 days until granulation tissue covers the exposed bone. Newer alternatives include chlorhexidine-impregnated gels and platelet-rich fibrin, but eugenol-based dressings remain the most widely used worldwide for cost and efficacy reasons.

Back to Table of Contents

Endodontic Applications — Root Canal Sealers

Endodontic (root canal) treatment requires obturating the cleaned and shaped root canal with a filling material that seals it against bacterial re-entry from the oral cavity and from the periapical tissues. The classical obturation technique uses gutta-percha cones as the core material together with a sealer cement that fills micro-irregularities between the gutta-percha and the canal wall. Several major sealer formulations are eugenol-based:

• Grossman's sealer — a zinc oxide eugenol formulation with added rosin, barium sulfate (for radiopacity), and bismuth subcarbonate. Long-standing standard endodontic sealer.
• Similar zinc oxide–eugenol root-canal sealers — ZOE-based formulations close to Grossman's, very widely used.
• Silver-containing zinc oxide–eugenol root-canal sealers — ZOE sealer with added precipitated silver for antimicrobial effect.
• Zinc oxide–eugenol root-canal sealers with other fillers — ZOE-based formulations with different filler chemistry.

Eugenol-based sealers have been the workhorse of endodontic practice for the better part of a century. Newer alternatives (calcium hydroxide-based, bioceramic, methacrylate resin sealers) have specific niche advantages, but eugenol-based sealers retain widespread use because of their proven long-term clinical performance, antimicrobial properties, dimensional stability, and ease of removal if retreatment becomes necessary. The trade-off is the same as with ZOE temporary restorations — eugenol inhibits the polymerization of methacrylate-based bonding agents and composite resins, so dental practice uses a non-resin material as the immediate coronal seal over eugenol-sealed root canals.

Back to Table of Contents

Practical Home Use — Whole Clove, Powder, and Diluted Oil

For occasional home use of clove against minor dental pain — a flare-up before a scheduled dentist visit, a lost filling needing temporary coverage, mild gum inflammation — these are the traditional and commonly described preparations:

• Whole dried clove bud — the simplest and historically dominant preparation. One whole bud is held against the painful tooth and bitten gently. The mechanical pressure releases the volatile oil at the contact point, producing analgesia within 60–90 seconds. It is spat out and replaced after 15–20 minutes as the analgesic effect wanes. People describe it as an adult remedy; a whole bud is a choking risk for children under 6.
• Powdered clove — a small amount sprinkled on the painful tooth, or mixed to a paste with a drop of olive oil and applied with a clean fingertip or cotton swab. The dose is easier to control than with whole buds. Same 15–20 minute duration of effect.
• Diluted clove essential oil — the home recipe is 2 drops of clove essential oil mixed into 1 teaspoon of olive oil, an approximately 1–2% eugenol concentration, dabbed with a cotton swab on the affected tooth or gum. Undiluted clove essential oil on the gums or inner cheek causes chemical burns of the mouth lining. The European Medicines Agency (EMA) clove-oil monograph describes undiluted oil only on a small piece of cotton placed into the decayed part of an aching tooth, avoiding contact with the gums.
• Clove water rinse — 5 cloves simmered in 250 mL water for 10 minutes, strained and cooled, used as a 30-second swish-and-spit rinse 2–3 times per day. Traditionally used for general gum inflammation; lower potency than direct application.

Home use of clove is a stop-gap, not a substitute for definitive dental care. Untreated dental caries, cracked teeth, or abscesses progress regardless of symptom control, and the EMA monograph calls toothache relief from clove oil “only a provisional measure,” limited to 1 week of use. Pain that lasts more than 48 hours, facial swelling, fever or feeling generally ill are signs of a spreading dental infection that dentists and hospitals treat as urgent — an untreated dental abscess can progress to cellulitis or in rare cases life-threatening Ludwig's angina (swelling under the tongue and jaw that can block breathing).

Back to Table of Contents

Cautions and Adverse Effects

• Undiluted essential oil causes mucosal burns — the single most common adverse event in home use of clove for dental pain. Home preparations for the gums dilute clove essential oil to 1–2% in a carrier oil, and the EMA monograph lists mouth irritation among reported side effects.
• Children, and swallowed clove oil — the EMA clove-oil monograph lists use in children and adolescents under 18 as not recommended, for lack of adequate data. Swallowed clove oil is a poisoning hazard for small children: the monograph records life-threatening conditions after 5–10 ml of clove oil was swallowed by children under 2, with depression of the nervous system (drowsiness to coma), urinary abnormalities, acid build-up in the blood (anion-gap acidosis), worsening liver function, seizures and low blood sugar. A 15-month-old boy developed sudden liver failure (fulminant hepatic failure) after swallowing 10 ml (Janes 2005), and a 7-month-old developed nervous-system depression and acidosis (Lane 1991). These are emergency signs that hospitals treat as urgent; the monograph notes reports of N-acetylcysteine used successfully as an antidote. Topical clove and eugenol products are not U.S. Food and Drug Administration-recommended for teething pain in infants. Benzocaine teething gels have been associated with methemoglobinemia and the U.S. Food and Drug Administration (FDA) has advised against all topical anesthetics for teething in children under 2 years.
• Allergic contact stomatitis — eugenol is a recognized contact allergen. A small fraction of patients develop a stomatitis with burning, redness, and ulceration of the oral mucosa after exposure. Patch testing in dermatology uses eugenol as part of "fragrance mix I." Symptoms that worsen with clove use rather than improving point to this reaction. The EMA monograph lists allergy to clove oil or to Peru balsam as a contraindication.
• Anticoagulant interaction — eugenol inhibits platelet aggregation. That raises a bleeding concern with concentrated clove preparations for people on warfarin, dabigatran, apixaban, rivaroxaban, or clopidogrel, particularly around dental procedures.
• ZOE incompatibility with composite restorations — when a temporary ZOE restoration is followed by a composite or bonded permanent restoration, dental practice removes the ZOE fully before bonding. Residual eugenol prevents methacrylate polymerization at the bonding interface.
• Pregnancy — culinary use of clove is ordinary food use; for clove essential oil, the EMA monograph states that safety during pregnancy and breastfeeding has not been established and, in the absence of sufficient data, its use then is not recommended.
• Pulpal toxicity at high concentration — ironically, while low-concentration eugenol is pulp-sedative, sustained exposure to high-concentration eugenol can cause pulpal necrosis in animal models. This is a theoretical concern with prolonged direct contact between concentrated eugenol and freshly exposed dentin; it has not been a clinical problem with standard dental ZOE materials used as recommended.

Back to Table of Contents

Key Research Papers

1. Alqareer A, Alyahya A, Andersson L (2006). The effect of clove and benzocaine versus placebo as topical anesthetics. Journal of Dentistry — PubMed PMID: 16530911
2. Markowitz K, Moynihan M, Liu M, Kim S (1992). Biologic properties of eugenol and zinc oxide-eugenol. A clinically oriented review. Oral Surgery Oral Medicine Oral Pathology. PubMed PMID: 1437045
3. Pramod K, Ansari SH, Ali J (2010). Eugenol: a natural compound with versatile pharmacological actions. Natural Product Communications. PubMed PMID: 21299140
4. Yang BH, Piao ZG, Kim YB, et al. (2003). Activation of vanilloid receptor 1 (VR1) by eugenol. Journal of Dental Research. PubMed PMID: 14514756
5. Park CK, Li HY, Yeon KY, et al. (2006). Eugenol inhibits sodium currents in dental afferent neurons. Journal of Dental Research. PubMed PMID: 16998128
6. Cai L, Wu CD (1996). Compounds from Syzygium aromaticum possessing growth inhibitory activity against oral pathogens. Journal of Natural Products. PubMed PMID: 8904847
7. Chaieb K et al. (2007). The chemical composition and biological activity of clove essential oil. Phytotherapy Research. PubMed
8. Lane BW, Ellenhorn MJ, Hulbert TV, McCarron M (1991). Clove oil ingestion in an infant. Human & Experimental Toxicology. PubMed PMID: 1679654
9. Janes SE, Price CS, Thomas D (2005). Essential oil poisoning: N-acetylcysteine for eugenol-induced hepatic failure and analysis of a national database. European Journal of Pediatrics. PubMed PMID: 15895251

PubMed Topic Searches

1. PubMed: Clove eugenol dental pain
2. PubMed: Zinc oxide eugenol cement
3. PubMed: Eugenol TRP channel desensitization
4. PubMed: Clove periodontitis and gingivitis
5. PubMed: Eugenol root canal sealer

Back to Table of Contents

Connections

• All Herbs
• Clove Benefits Hub
• Clove Overview
• Clove as Digestive Aid
• Clove Antioxidant Capacity
• Clove Antimicrobial Spectrum
• Antibacterial Herbs
• Myrrh (Traditional Oral Antiseptic)
• Tea Tree (Oral Antimicrobial)
• Thyme
• Cinnamon
• Oregano
• Streptococcus Pyogenes
• Staphylococcus Aureus
• Oxidative Stress
• Zinc
• Inflammatory Markers
• History

Back to Table of Contents

Featured Videos

×